As we learned from the KEYNOTE-189 study, even patients with a PD-L1 status of <1% benefit from combination therapy with pembrolizumab in terms of overall survival and tumor response, which in the case of our patient led to the decision to adopt an individualized therapy approach [6]. The gene discussed is CD274; the disease is neoplasm.